World Health Organization, Data and statistics profile idn en
Indonesia
South-East Asia Region
I. Epidemiological profile
Population (UN)
High transmission (> 1 case per 1000 population)
2015
Parasites and vectors
30,300,000
%
12
Plasmodium species:
P. falciparum (55%), P.vivax (44%)
Low transmission (0-1 cases per 1000 population)
37,000,000
14
Major anopheles species:
An. sundaicus, An. balabacensis, An. maculatus, An. farauti, An. subpictus, An. subpictus
Malaria-free (0 cases)
190,000,000
74
Reported confirmed cases (health facility):
Total
257,560,000
217,025
Confirmed cases at community level:
Estimated cases:
1,300,000 [990,000 ; 1,600,000]
Estimated deaths:
1,900 [160 ; 3,600]
-
Reported deaths:
157
II. Intervention policies and strategies
Intervention
Policies/strategies
ITN
IRS
Yes/No
Adopted
ITNs/ LLINs distributed free of charge
Yes
First-line treatment of unconfirmed malaria
ITNs/ LLINs distributed to all age groups
Yes
2004
2004
IRS is recommended
Yes
1959
Treatment failure of P. falciparum
No
-
DDT is authorized for IRS
Use of larval control recommended
Yes
1990
IPT
IPT used to prevent malaria during pregnancy
N/A
-
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
1959
ACT is free of charge for all ages in public sector
Yes
2004
Never allowed
2010
Single dose of primaquine is used as gametocidal medicine for
P. falciparum
Yes
2004
Primaquine is used for radical treatment of P. vivax
Yes
2004
G6PD test is a requirement before treatment with primaquine
No
-
Directly observed treatment with primaquine is undertaken
No
-
System for monitoring adverse reactions to antimalarials exists
Yes
2016
ACD for case investigation (reactive)
Yes
1965
ACD of febrile cases at community level (pro-active)
Yes
1965
Mass screening is undertaken
Yes
1965
Uncomplicated P. falciparum cases routinely admitted
Yes
1990
Uncomplicated P. vivax cases routinely admitted
Yes
1990
-
-
Yes
1984
The sale of oral artemisinin-based monotherapies (oAMTs)
Surveillance
Foci and case investigation undertaken
Case reporting from private sector is mandatory
First-line treatment of P. falciparum
Treatment of severe malaria
Larval control
Treatment
Antimalarial treatment policy
Treatment of P. vivax
Year adopted
-
-
DHA-PP+PQ
2008
QN+D+PQ
2004
AM; AS; QN
2004
DHA-PP+PQ(14d)
2008
Dosage of Primaquine for radical treatment of P. vivax
0.25 mg/Kg (14 days)
Type pf RDT used
P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Year
Medicine
Min
Median
Max
Follow-up
No of studies
Species
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
Pyrethroid DDT Carbamate Organophosphate Species/complex tested
2011–2014
Yes
No
Sources of financing
III. Financing
Medicine
Yes
No
An. subpictus s.l., An. sundaicus s.l., other
Government expenditure by intervention in 2015
Contribution ($USm)
50
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and Evaluation
Human Resources & Technical Assistance
Management and other costs
40
30
20
10
Pie chart includes 32% of total expenditures
0
2005
2006
Gov. expend.
2007
2008
Global Fund
2010
World Bank
IV. Coverage
2011
USAID/PMI
2012
2013
WHO/UNICEF
2014
2015
Others
Coverage of ITN and IRS
Cases tested and treated in public sector
100
100
80
80
60
60
(%)
Population (%)
2009
40
40
20
20
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2005
2015
2006
2007
2008
2010
2011
2012
2013
2014
2015
Source: DHS 2007, DHS 2012, Other Nat.*
Source: DHS 2007
At high risk protected with ITNs
Households with at least one ITN (survey)
V. Impact
Suspected cases tested
%
South-East Asia Region
I. Epidemiological profile
Population (UN)
High transmission (> 1 case per 1000 population)
2015
Parasites and vectors
30,300,000
%
12
Plasmodium species:
P. falciparum (55%), P.vivax (44%)
Low transmission (0-1 cases per 1000 population)
37,000,000
14
Major anopheles species:
An. sundaicus, An. balabacensis, An. maculatus, An. farauti, An. subpictus, An. subpictus
Malaria-free (0 cases)
190,000,000
74
Reported confirmed cases (health facility):
Total
257,560,000
217,025
Confirmed cases at community level:
Estimated cases:
1,300,000 [990,000 ; 1,600,000]
Estimated deaths:
1,900 [160 ; 3,600]
-
Reported deaths:
157
II. Intervention policies and strategies
Intervention
Policies/strategies
ITN
IRS
Yes/No
Adopted
ITNs/ LLINs distributed free of charge
Yes
First-line treatment of unconfirmed malaria
ITNs/ LLINs distributed to all age groups
Yes
2004
2004
IRS is recommended
Yes
1959
Treatment failure of P. falciparum
No
-
DDT is authorized for IRS
Use of larval control recommended
Yes
1990
IPT
IPT used to prevent malaria during pregnancy
N/A
-
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
1959
ACT is free of charge for all ages in public sector
Yes
2004
Never allowed
2010
Single dose of primaquine is used as gametocidal medicine for
P. falciparum
Yes
2004
Primaquine is used for radical treatment of P. vivax
Yes
2004
G6PD test is a requirement before treatment with primaquine
No
-
Directly observed treatment with primaquine is undertaken
No
-
System for monitoring adverse reactions to antimalarials exists
Yes
2016
ACD for case investigation (reactive)
Yes
1965
ACD of febrile cases at community level (pro-active)
Yes
1965
Mass screening is undertaken
Yes
1965
Uncomplicated P. falciparum cases routinely admitted
Yes
1990
Uncomplicated P. vivax cases routinely admitted
Yes
1990
-
-
Yes
1984
The sale of oral artemisinin-based monotherapies (oAMTs)
Surveillance
Foci and case investigation undertaken
Case reporting from private sector is mandatory
First-line treatment of P. falciparum
Treatment of severe malaria
Larval control
Treatment
Antimalarial treatment policy
Treatment of P. vivax
Year adopted
-
-
DHA-PP+PQ
2008
QN+D+PQ
2004
AM; AS; QN
2004
DHA-PP+PQ(14d)
2008
Dosage of Primaquine for radical treatment of P. vivax
0.25 mg/Kg (14 days)
Type pf RDT used
P.f + all species (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Year
Medicine
Min
Median
Max
Follow-up
No of studies
Species
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
Pyrethroid DDT Carbamate Organophosphate Species/complex tested
2011–2014
Yes
No
Sources of financing
III. Financing
Medicine
Yes
No
An. subpictus s.l., An. sundaicus s.l., other
Government expenditure by intervention in 2015
Contribution ($USm)
50
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and Evaluation
Human Resources & Technical Assistance
Management and other costs
40
30
20
10
Pie chart includes 32% of total expenditures
0
2005
2006
Gov. expend.
2007
2008
Global Fund
2010
World Bank
IV. Coverage
2011
USAID/PMI
2012
2013
WHO/UNICEF
2014
2015
Others
Coverage of ITN and IRS
Cases tested and treated in public sector
100
100
80
80
60
60
(%)
Population (%)
2009
40
40
20
20
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2005
2015
2006
2007
2008
2010
2011
2012
2013
2014
2015
Source: DHS 2007, DHS 2012, Other Nat.*
Source: DHS 2007
At high risk protected with ITNs
Households with at least one ITN (survey)
V. Impact
Suspected cases tested
%